Dr Andrew Mortlock

Dr. Andrew Mortlock is Executive Vice President and Head of Early Development at Astellas with accountability for Phase 1 and 2 studies with a range of modalities including small molecules, antibodies, cell and gene therapies. Previously he was Global Franchise Head in AstraZeneca’s Late Development Oncology Unit with global responsibility for Phase 3 development projects. During a varied career with AstraZeneca he was VP for Hematology Projects, VP for Oncology Combinations and VP for Oncology Projects (small molecules). A pre-clinical scientist by training, he had previously led the Chemistry team that developed the selective Aurora B kinase inhibitor AZD1152 and also led the Alderley Park Oncology research group before moving to development roles in 2010. Dr Mortlock played a significant role in the notable development of Osimertinib (EGFRm), Acalabrutinib (BTK), Selumetinib (MEK) and Savolitinib (cMet), all of which have been approved for the treatment of cancer. Apart from his assignments at AstraZeneca, Andrew also served as Chief Scientific Officer at Acerta Pharma.